Study 4 of 5Pemvidutide literatureLancet (London, England) · Phase 2Top journal2025
The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial.
Not reported in abstract.
Where it sits
this study against the rest of the pemvidutide corpus0
Preclinical
1
Observational
1
Open-label · this one
1
Randomised
2
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
Phase 22025
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Pemvidutide corpus
ASafety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.Lancet (London, England) · 2025 · MASH resolution without fibrosis worsening: 58% in 1.2 mg pemvidutide group, p<0.0001.HumanDGlucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov.Addictive behaviors reports · 2026 · Not reported in abstract.reviewDEfficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials.Naunyn-Schmiedeberg's archives of pharmacology · 2026 · -52.90 MD liver fat content at 12 weeks, 95% CI -71.60 to -34.20, P < 0.00001reviewDEfficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.Cureus · 2026 · RR 3.32, 95% CI 2.28-4.84; I² = 20% for MASH resolution or histological improvement without worsening of fibrosis.review